NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy
NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma
NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma
NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
NCT04302324: Phase 2: Daratumumab, Clarithromycin, Pomalidomide And Dex RRMM - D-ClaPd
NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dex RRMM
NCT04499339: Phase 1/2: Autologous SLAMF7 CAR-T Cells in Multiple Myeloma - RRMM - CARAMBA-1
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM